Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Small cell lung cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,319 result(s) found for: Small cell lung cancer. Displaying page 6 of 66.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2008-004008-30 Sponsor Protocol Number: A4021017 Start Date*: 2009-10-29
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: RANDOMIZED, OPEN LABEL, PHASE 3 CLINICAL STUDY TO EVALUATE THE EFFECT OF THE ADDITION OF CP-751,871 TO GEMCITABINE AND CISPLATIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Medical condition: Metastic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000765-33 Sponsor Protocol Number: AGMT_NSCLC 1 Start Date*: 2009-11-19
    Sponsor Name:AGMT gemeinnützige GmbH
    Full Title: Phase II Study to Investigate the Treatment of Patients with NSCLC Stage IIIB and IV without the Option of Surgery with a Combination of Cisplatin, Docetaxel and Bevacizumab
    Medical condition: Inoperable NSCLC, stages IIIB and IV
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029521 Non-small cell lung cancer stage IIIB LLT
    12.0 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000617-30 Sponsor Protocol Number: MCC-15005 Start Date*: 2008-09-25
    Sponsor Name:Klinik Loewenstein gGmbH
    Full Title: Randomized Phase III Multicenter Trial of RRM1 & ERCC1 Directed Customized Chemotherapy versus Standard of Care for 1st Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer
    Medical condition: Patients with untreated advanced stage NSCLC. 2:1 randomization to experimental (A) or standard arm (B). In arm A, treatment of dual-agent chemotherapy will be selected based on RRM1 and ERCC1 ex...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009315-22 Sponsor Protocol Number: NVALT10 Start Date*: 2009-02-25
    Sponsor Name:NVALT
    Full Title: A randomized phase II study of erlotinib compared to single agent chemotherapy-erlotinib combination in pretreated patients with advanced NSCLC (NVALT10 study)
    Medical condition: patients who failed previous cytotoxic treatment for non-small-cell lung cancer locally advanced and metastatic disease stage IIIB and IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004167-22 Sponsor Protocol Number: PGT307 Start Date*: 2008-01-23
    Sponsor Name:Cell Therapeutics, Inc.
    Full Title: Paclitaxel poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with Estradiol > 30 pg/ml
    Medical condition: Advanced Non-small Cell Lung Cancer (NSCLC) in women.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000804-41 Sponsor Protocol Number: CECOG/NSCLC.3.2.002 Start Date*: 2004-12-30
    Sponsor Name:CECOG
    Full Title: Phase II Trial of Dose-Dense Paclitaxel and Cisplatin as Neo-Adjuvant Chemotherapy for Operable Stage II and IIIA Non-Small Cell Lung Cancer
    Medical condition: Operable Stage II and IIIA Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061873 NSLC
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006682-33 Sponsor Protocol Number: A4061030 Start Date*: 2008-03-20
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
    Full Title: Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer
    Medical condition: First line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005586-75 Sponsor Protocol Number: CSET2014/2204_PIPSeN Start Date*: 2015-10-08
    Sponsor Name:Gustave Roussy
    Full Title: A Randomized double-blind Phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer
    Medical condition: Advanced non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10025052 Lung cancer non-small cell stage III LLT
    18.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001642-28 Sponsor Protocol Number: INCB39110-205 Start Date*: 2015-09-28
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer Whose Tu...
    Medical condition: Male or female individuals, aged 18 years or older who have Stage IIIB/IV or recurrent NSCLC. Subjects must have tumors that are positive for EGFR-activating mutation, namely, exon 19 deletions, e...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001922-40 Sponsor Protocol Number: CLDK378A2X01B Start Date*: 2016-01-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the invest...
    Medical condition: non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Completed) BE (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001264-37 Sponsor Protocol Number: 1200.40 Start Date*: 2008-11-20
    Sponsor Name:BOEHRINGER ING.
    Full Title: A Phase II single-arm trial of BIBW 2992(Tovok) in EGFR FISH positive non-small cell lung cancer patients
    Medical condition: Patients affected by NSCLC EGFR FISH positive.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004592-11 Sponsor Protocol Number: IGN101/2-02 Start Date*: 2005-02-16
    Sponsor Name:IGENEON
    Full Title: Vaccination with IGN101 in patients with non-small-cell-lung-cancer (NSCLC)
    Medical condition: Non-small-cell-lung-cancer stages IB, II A/B, III A
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061873 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002941-20 Sponsor Protocol Number: GEST Start Date*: 2007-05-28
    Sponsor Name:SECONDA UNIVERSITA' DEGLI STUDI DI NAPOLI
    Full Title: RANDOMIZED PHASE II STUDY OF SORAFENIB PLUS GEMCITABINE OR SORAFENIB PLUS ERLOTINIB IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) ELDERLY OR PS 2 PATIENTS
    Medical condition: ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) ELDERLY OR PS 2 PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061873 PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001044-72 Sponsor Protocol Number: XRP6976B/2506 Start Date*: 2005-01-17
    Sponsor Name:AVENTIS PHARMA S.P.A.
    Full Title: Randomized phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
    Medical condition: Non Small Cell Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061873 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002811-98 Sponsor Protocol Number: CALC-1 Start Date*: 2005-07-01
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
    Full Title: Randomised phase II study of cetuximab in combination with gemcitabine or gemcitabine followed by cetuximab in patients with advanced non-small-cell lung cancer, not suitable for standard platin-ba...
    Medical condition: Patients with advanced non-small-cell lung cancer, not suitable for standard platin-based therapy.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061873 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003250-15 Sponsor Protocol Number: 48/2008/O/Sper Start Date*: 2008-06-24
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: SEQUENTIAL CHEMOTHERAPY WITH CISPLATIN PLUS VINORELBINE FOLLOWED BY WEEKLY DOCETAXEL IN LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER
    Medical condition: locally advanced or metastatic NSCLC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005027-18 Sponsor Protocol Number: 1147/04 Start Date*: 2005-03-20
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: CONCURRENT RADIOCHEMIOTHERAPHY AND SURGERY IN NSCLC . A PHASE II MULTICENTRIC STUDY
    Medical condition: neoadiuvant treatment for locally advanced nsclc
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041068 Small cell lung cancer extensive stage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024061-48 Sponsor Protocol Number: ML25423 Start Date*: 2011-05-25
    Sponsor Name:Roche Bulgaria EOOD
    Full Title: Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who present activating mutations in the tyrosine k...
    Medical condition: Locally advanced or metastatic NSCLC of stage IIIb or IV or recurrent NSCLC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-006323-31 Sponsor Protocol Number: D1532C00016 Start Date*: 2009-05-19
    Sponsor Name:AstraZeneca AB
    Full Title: D1532C00016: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line...
    Medical condition: 2nd Line Patients with KRAS Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002597-44 Sponsor Protocol Number: CFZ004 Start Date*: 2014-02-10
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer
    Medical condition: Untreated extensive stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) HU (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 13:03:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA